Clinical Trial Update: Risedronate in Improving Bone Mineral Density and Bone Health in Postmenopausal Women With Ductal Carcinoma In Situ Enrolled in Clinical Trial CRUK-IBIS-II-DCIS [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating risedronate to improve bone mineral density in postmenopausal women with ductal carcinoma in situ has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Ductal Carcinoma in Situ
• Osteoporosis

Drugs mentioned

• risedronate (risedronate)

Snippet

Sponsor: ETOP IBCSG Partners Foundation | Conditions: Breast Cancer, Osteoporosis | Phase 3 | Status: WITHDRAWN